Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases

Author(s): Ignacio Perez-Roger , Carmen Ivorra , Antonio Diez , Maria Jose Cortes , Enric Poch , Silvia M. Sanz-Gonzalez , Vicente Andres .

Journal Name: Current Pharmaceutical Biotechnology

Volume 1 , Issue 1 , 2000

Become EABM
Become Reviewer

Abstract:

Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.

Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 1
ISSUE: 1
Year: 2000
Page: [107 - 116]
Pages: 10
DOI: 10.2174/1389201010001010107

Article Metrics

PDF: 12